In ME/CFS patients, severe alterations of the muscle excitability, the redox status, as well as the CD26-expression level are correlated with a marked impairment of the quality-of-life. The gene discussed is DPP4; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.